Quarterly report [Sections 13 or 15(d)]

Basis of Presentation (Details)

v3.25.3
Basis of Presentation (Details) - USD ($)
3 Months Ended 12 Months Ended
Aug. 19, 2025
Apr. 29, 2025
Jan. 10, 2025
Sep. 30, 2025
Sep. 30, 2024
Jun. 30, 2025
Jul. 03, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Net cash used in operations       $ 5,665,000 $ 3,715,000    
Total current assets       50,772,000   $ 9,721,000  
Cash and cash equivalents       28,111,000   $ 8,582,000  
Debt securities       21,456,000      
Cash, cash equivalents, and investments in debt securities       49,600,000      
Net loss from operations       $ 5,700,000      
Common stock, par value       $ 0.001   $ 0.001  
At Market Issuance Sales Agreement | Placement Agents | At-The-Market Offerings | Common Stock              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Aggregate offering price             $ 7,350,000
Common stock, shares issued       305,424   3,184,899  
Net proceeds from sale of equity       $ 219,000   $ 2,617,000  
2025 Purchase Agreement | Investors | Private placement | Common Stock              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Common stock, shares issued     240,807        
Share price on new issues     $ 2.72        
Aggregate gross proceeds     $ 655,000        
Warrant Inducement Agreement | Pre-Funded Warrants              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Warrants, exercise price   $ 0.86          
Warrants, shares issued   5,626,685          
Warrant Inducement Agreement | Inducement Warrants              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Warrants, exercise price   $ 0.86          
Proceeds per share (inducement warrants)   $ 0.125          
Proceeds from exercise of warrants   $ 6,200,000          
Warrants, shares issued   11,253,370          
Inducement warrants conversion percentage to common shares   200.00%          
Warrants, exercisable term   5 years          
2025 Underwriting Agreement | Leerink Partners | At-The-Market Offerings              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Gross proceeds from sale of equity $ 50,000,000            
Net proceeds from sale of equity $ 46,400,000            
2025 Underwriting Agreement | Leerink Partners | At-The-Market Offerings | Common Stock              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Common stock, shares issued 71,540,000            
Warrants, shares exercised       0      
2025 Underwriting Agreement | Leerink Partners | At-The-Market Offerings | Common Stock | Series G Warrants              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Warrants, shares issued 35,770,000            
2025 Underwriting Agreement | Leerink Partners | At-The-Market Offerings | Common Stock | Series G Warrants | Minimum              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Warrants, exercisable term 30 days            
2025 Underwriting Agreement | Leerink Partners | At-The-Market Offerings | Common Stock | Series G Warrants | Maximum              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Warrants, exercisable term 5 years            
2025 Underwriting Agreement | Leerink Partners | At-The-Market Offerings | Common Stock | Series H Warrants              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Warrants, shares issued 35,770,000            
Warrants, exercisable term 4 years